deltatrials
Completed PHASE3 NCT00131326

A Study of the Safety and Efficacy of Synvisc and Depo-Medrol in Patients With Osteoarthritis of the Hip

Sponsor: Genzyme, a Sanofi Company

Conditions Musculoskeletal Diseases Osteoarthritis, Hip
Interventions Synvisc (hylan G-F 20)
Updated 7 times since 2017 Last updated: Jul 27, 2017 Started: Nov 30, 2003 Completion: Apr 30, 2006

A PHASE3 clinical study on Musculoskeletal Diseases and Osteoarthritis, Hip, this trial is completed. The trial is conducted by Genzyme, a Sanofi Company and has accumulated 7 data snapshots since 2003. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 2 earlier versions

  1. Sep 2017 — Jun 2018 [monthly]

    Completed PHASE3

  2. Jan 2017 — Sep 2017 [monthly]

    Completed PHASE3

    First recorded

Nov 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Genzyme, a Sanofi Company
Data source: Sanofi

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baltimore, United States, Birmingham, United States, Cedar Rapids, United States, Chattanooga, United States, Chicago, United States, Clearwater, United States, Columbus, United States, Conway, United States, Duncansville, United States, Flint, United States and 22 more location s